Company intelligence / Profile preview

Promis Diagnostics

Irvine, California, United States

Ownership: Private
Development stage: Other

Overview

Promis Diagnostics develops and commercializes noninvasive, PCR-based diagnostic tests for early detection of colorectal, bladder, and lung cancers using patented LTE-qMSP technology to identify methylated DNA biomarkers with high sensitivity and specificity. Its EarlyTect® BCD test for bladder cancer has been recognized in clinical guidelines as a validated urinary biomarker option.

Therapeutic areas: Oncology
Modalities: Diagnostic testPCR-basedMethylation biomarker detection
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Promis Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Promis Diagnostics.

Explore the full profile